Efficacy and safety of Guduchighan Vati in asymptomatic and mild to moderate cases of COVID-19: A randomized controlled pilot study

Shukla, Umesh; Ujjaliya, Nitin; Gupta, Pankaj; Khare, Vivek; Yadav, Babita; Kumar, Amit; Amin, Hetal; Rana, Rakesh; Tripathi, Arunabh; Sharma, Bhagwan Sahai; Khanduri, Shruti; Chandrasekhararao, Bhogavalli; Srikanth, Narayanam; Dhiman, Kartar Singh

doi:10.31219/osf.io/c8f9h

Cited by 3 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One report was excluded during the data extraction process, which used AYUSH interventions as a comparator, 16 finally 12 manuscripts were included. [17][18][19][20][21][22][23][24][25][26][27][28] Detail description of the study selection and elimination process has been depicted in figure 1. All the articles were in the English language only.…”

Section: Study Characteristicsmentioning

confidence: 99%

“…Among included studies of the therapeutic domain, 2 RCTs examined the benefit of AYUSH-64, 17,18 2 studies (1 RCT, 1 NRSI) of Guduchi Ghanavati, 19,20 each one RCT on different multiple Combinations of Ayurveda medicines (coded as AYUSH regimen-I, II, III, IV, V, VI, and VII). [21][22][23][24][25][26] AYUSH Regimen III and IV were examined in a single RCT.…”

Section: Figure 1: Prisma Flow Chartmentioning

confidence: 99%

“…Four articles were peer-reviewed published manuscripts, 21,22,24,26 one was pre-proof,23 and seven were pre-print. [17][18][19][20]25,27,28 Among all, 6 studies were add-on AYUSH interventions studies 17,18,21,[24][25][26] and 6 were standalone interventions. 19,20,22,23,27,28 One study reported with placebo control 22 whereas eleven reported standard of care as a comparator.…”

Section: Figure 1: Prisma Flow Chartmentioning

confidence: 99%

“…Among 9 RCTs, 6 studies had a high risk of bias associated with measurements of the outcomes or selection of the reported results, 17,[22][23][24][25][26] remaining studies had some concerns (Figure 2). 18,19,27 Out of 3 NRSIs, 1 study had a high risk of bias associated with the selection of participants and measurements of the outcomes 20 whereas other studies had some concerns (Figure 3). 21,28 No study had a low risk of bias in this systematic review.…”

Section: Quality/risk Of Bias Of Included Studiesmentioning

confidence: 99%

“…Sensitivity analysis suggested findings were robust and did not alter overall results. (Table 5) 19,20,22,23,27,28 other six on add-on AYUSH interventions. 17,18,21,[24][25][26] Among conglomerate of AYUSH system; we find research manuscripts only on Ayurveda and Siddha discipline.…”

Section: Subgroup and Sensitivity Analysismentioning

confidence: 99%

See 4 more Smart Citations

AYUSH interventions for COVID-19 - a living systematic review and meta-analysis [First report]

Thakar¹,

Panara²,

Goyal³

et al. 2022

Preprint

View full text Add to dashboard Cite

BackgroundIn India, alternative and complementary therapies (AYUSH medicines) are utilized in COVID-19 management extensively. This study was planned to assess the prophylactic and therapeutic effectiveness of AYUSH interventions on COVID-19 through a living systematic review and meta-analysis approach.MethodsDifferent databases like Pubmed; the Cochrane central register of controlled trials; WHO COVID-19 database; the central trial registry - India; Digital Helpline for Ayurveda Research Articles and AYUSH research portal, and pre-print repositories were searched with appropriate search strategies from 1st December 2019 to 1st April 2021. Randomized clinical trials, Non-Randomized Studies of Interventions conducted on the AYUSH system of medicine aimed at either prevention or treatment were included. Clinical improvement, WHO ordinal scale, viral clearance, incidences of COVID-19 infection, and mortality will be considered as primary outcomes. Secondary outcomes will be the use of O2 therapy or mechanical ventilator, admission to high dependency unit or emergency unit, duration of hospitalization, the time to symptom resolution, and adverse events. Data will be synthesized, and the risk of bias will be assessed with RevMan 5.4 tool. The risk of bias of included studies was evaluated by RoB-2 and ROBINS-I tools, and the certainty of the evidence ranked through the GRADE approach.ResultsOf 2,977 studies retrieved, only 12 studies were included in the systematic review. In a moderately certain trial on standalone AYUSH versus Standard care, viral clearance was hastened in the standalone AYUSH group. Add-on AYUSH had shortened time to symptom resolution by about two days compared to standard care with moderate certainty. However, Add-on AYUSH intervention may hasten clinical improvements but has little to no effects on viral clearance. AYUSH prophylaxis may reduce the risk of COVID-19 with low certainty.ConclusionRational use of integrated or standalone AYUSH interventions in mild to moderate COVID-19 patients may provide therapeutic benefits. The effect of AYUSH prophylaxis in the reduction of incidence of COVID-19 in high-risk populations is uncertain. The effect estimates may be changed with additional evidence in upcoming updates.

show abstract

Section: Study Characteristicsmentioning

confidence: 99%

Section: Figure 1: Prisma Flow Chartmentioning

confidence: 99%

Section: Figure 1: Prisma Flow Chartmentioning

confidence: 99%

Section: Quality/risk Of Bias Of Included Studiesmentioning

confidence: 99%

Section: Subgroup and Sensitivity Analysismentioning

confidence: 99%

See 3 more Smart Citations

AYUSH interventions for COVID-19 - a living systematic review and meta-analysis [First report]

Thakar¹,

Panara²,

Goyal³

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

An Insight of Clinical Evidence of Ayurveda Interventions in the Management of COVID-19 Patients

Maideen

Balasubramaniam²,

Manavalan³

et al. 2022

IDDT

View full text Add to dashboard Cite

Background: Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) caused Coronavirus disease 2019 (COVID-19) and the patients with COVID-19 might be managed with traditional medicine like Ayurveda alone or in combination with standard allopathic treatment as Ayurveda is one of the oldest traditional medicinal systems followed by millions around the globe. Methods: The literature was searched in databases such as LitCOVID, Google Scholar, Science Direct, EBSCO, Scopus, Web of science, EMBASE, and reference lists to identify articles relevant to the use of Ayurvedic medicines in the management of COVID-19. Results: Several clinical studies have determined the efficacy of Ayurvedic medicines and formulations in the management of patients with COVID-19. Conclusion: The Ayurvedic medicines and formulations having antiviral, antioxidant, anti-inflammatory, and immunomodulatory properties could be used along with standard allopathic medicines to assist in the earlier clearance of virus, speedy recovery of patients with COVID-19, faster discharge from hospitals, and the prevention of further deterioration.

show abstract

Potential role of tinospora cordifolia in management of COVID-19

Singh

Sharma

2022

ijhs

View full text Add to dashboard Cite

Background: Tinospora cordifolia has gained popularity as an immunomodulatory and protective herb. Being anIndian traditional herb, it has found its use in Ayurveda and alternative system of medicine. According to World Health Organization, still 80% of the world population relies on alternative therapies for disease and infirmity. Dearth of medicine and treatment for COVID-19 has pushed researcher towards alternative therapies. This review focuses on the potential role of T.cordifolia in management of Coronavirus disease. Methods:A systematic review has been carried out by searching Google Scholar and SCOPUS Database from the year 2020 onwards. The review is written following the PRISMA Guidelines. Results:A total of 20 studies have been included in the systematic review. These studies are mainly based on molecular docking (in-silico studies), narrative reviews, retrospective studies, animal experimentation and randomized controlled trials. All the studies reported promising results. In silico studies covered the activity of phytochemicals in T.cordifolia and their inhibitory action on viral replication and binding. The experimental studies also showed positive results in human as well as animal models.

show abstract

Efficacy and safety of Guduchighan Vati in asymptomatic and mild to moderate cases of COVID-19: A randomized controlled pilot study

Cited by 3 publications

References 0 publications

AYUSH interventions for COVID-19 - a living systematic review and meta-analysis [First report]

AYUSH interventions for COVID-19 - a living systematic review and meta-analysis [First report]

An Insight of Clinical Evidence of Ayurveda Interventions in the Management of COVID-19 Patients

Potential role of tinospora cordifolia in management of COVID-19

Contact Info

Product

Resources

About